Artificial Intelligence in Cervical Cytology: Opportunities and Limitations in Screening, Triage, and Diagnostic Support
Diagnostics · 19.05.2026 · 16 (10) · 1541
DOI: 10.3390/diagnostics16101541 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 19.05.2026. Verfasst von Agata Stanek-Widera und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Academy of Silesia, 40-555 Katowice, Poland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cervical cancer remains a major global health challenge, particularly in low- and middle-income countries, where access to screening, vaccination, and timely treatment may be limited. Cervical cytology has played an important historical role in prevention, but it is labor-intensive, time-consuming, and subject to observer variability and limited sensitivity. In many contemporary screening programs, HPV testing is now used as the primary screening test, while cytology is used mainly for the triage of HPV-positive women. In recent years, artificial intelligence (AI), particularly deep learning (DL), has shown considerable potential in medical image analysis and computer-aided diagnosis. This review summarizes current applications of AI in cervical cytology and related diagnostic workflows, including automated and assisted slide screening, liquid-based cytology, the triage of equivocal or HPV-positive cases, and colposcopy support. Across these settings, AI-assisted systems may improve efficiency, standardization, and diagnostic consistency, and may reduce workload in resource-constrained environments. However, the evidence is heterogeneous, and important challenges remain, including the need for large and diverse datasets, prospective validation, regulatory approval, digital infrastructure, workflow integration, and the resolution of ethical and legal issues. AI should therefore be regarded as a promising adjunct to human expertise rather than a replacement in cervical cytology and related clinical diagnostic pathways.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Academy of Silesia, 40-555 Katowice, Poland.
- Faculty of Medicine, Bydgoszcz University of Science and Technology, Aleje Prof. S. Kaliskiego 7, 85-796 Bydgoszcz, Poland.
- Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, 05-552 Magdalenka, Poland.
- Department of Obstetrics, Gynaecology and Oncology, Collegium Medicum, Nicolaus Copernicus University in Bydgoszcz, 85-067 Bydgoszcz, Poland.
- Department of Pathology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan.
- Department of Medicine Solna, Karolinska Institute, 171 77 Stockholm, Sweden.
ORCID-Profile: Agata Stanek-Widera, Jędrzej Borowczak, Dominik Skiba, Michel-Edwar Mickael, Mateusz Maniewski, Łukasz Szylberg, Andrey Bychkov
Zitieren
APA
Stanek-Widera, A., Borowczak, J., Skiba, D., Mickael, M. E., Łazarczyk, M., Maniewski, M., Szylberg, Ł., Bychkov, A., & Religa, P. (2026). Artificial Intelligence in Cervical Cytology: Opportunities and Limitations in Screening, Triage, and Diagnostic Support. Diagnostics, 16(10), 1541. https://doi.org/10.3390/diagnostics16101541
Vancouver
Stanek-Widera A, Borowczak J, Skiba D, Mickael ME, Łazarczyk M, Maniewski M, et al. Artificial Intelligence in Cervical Cytology: Opportunities and Limitations in Screening, Triage, and Diagnostic Support. Diagnostics. 2026;16(10):1541. doi:10.3390/diagnostics16101541
BibTeX
@article{StanekWidera2026,
author = {Stanek-Widera, Agata and Borowczak, Jędrzej and Skiba, Dominik and Mickael, Michel-Edwar and Łazarczyk, Marzena and Maniewski, Mateusz and Szylberg, Łukasz and Bychkov, Andrey and Religa, Piotr},
title = {Artificial Intelligence in Cervical Cytology: Opportunities and Limitations in Screening, Triage, and Diagnostic Support},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {10},
pages = {1541},
doi = {10.3390/diagnostics16101541}
}
EUVIMED